Opdivo Set To Break $1bn Japan Barrier On Lung Cancer Use
This article was originally published in PharmAsia News
Sales of immuno-oncology drug Opdivo in Japan are surpassing even Ono's raised projections and seem set to head for the stars following major new indications, although potential one-off price cuts are casting a shadow over the expected stellar growth.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.